Collaborative Science

PCS worked with LumiThera’s scientists and near infrared light (NIR) experts to make the LT-300 a functional reality.  The PCS team integrated LumiThera’s optics and light drivers, designing and engineering the platform, housing, patient interface, system electronics and firmware for proof-of-concept prototypes.  Our teams then tested and optimized devices for early test and review by LumiThera’s board of medical experts.

Improving Lives

The collaboration between LumiThera and PCS achieved the next phase commercialization grant from LSDF and for our part PCS won the Most Innovative Company out of 2200 companies attending  the MDM West Conference.  Lumithera is now conducting human testing and in the Design for Manufacture (DFM) stage.  PCS is proud to be part of the LumiThera team that will be the first to commercialize this impactful, non-invasive light treatment.  This life-changing work will address vision loss, prevent blindness and improve the quality of life for people affected by macular degeneration.

In a late 2017 30-subject pilot study, LumiThera's LT-300 device posted topline, clinical interim data proving PBM improved the vision of dry AMD patients. You can read more about the study details and results in our blog post: Congrats to Client LumiThera on Posting Positive Clinical Interim Data!

"LumiThera had a vision of what we wanted to build and PCS listened and worked with our team over the last year to create something very special… The experience is an example of how the development process should work." - LumiThera